- Exchange: NASDAQ GS
- Sector: Consumer, Non-cyclical
- Industry: Biotechnology
- Sub-Industry: Medical-Biomedical/Gene
Biogen Idec Inc
+ Add to WatchlistBIIB:US
226.8500 USD 1.1400 0.50%As of 20:10:00 ET on 05/17/2013.
Snapshot for Biogen Idec Inc (BIIB)
| Open: | 228.3600 | Day's Range: | 224.6000 - 228.8600 | Volume: | 1,243,879 |
|---|---|---|---|---|---|
| Previous Close: | 226.8500 | 52wk Range: | 126.3900 - 231.9900 | 1-Yr Rtn: | +72.40% |
Key Statistics for BIIB
| Current P/E Ratio (ttm) | 36.3664 |
|---|---|
| Estimated P/E(12/2013) | 28.5525 |
| Relative P/E vs. SPX | 2.2289 |
| Earnings Per Share (USD) (ttm) | 6.2379 |
| Est. EPS (USD) (12/2013) | 7.9450 |
| Est. PEG Ratio | 1.5310 |
| Market Cap (M USD) | 53,848.48 |
| Shares Outstanding (M) | 237.37 |
| 30 Day Average Volume | 1,332,102 |
| Price/Book (mrq) | 7.3373 |
| Price/Sale (ttm) | 9.5425 |
| Dividend Indicated Gross Yield | -% |
| Cash Dividend | - |
| Last Dividend | |
| 5 Year Dividend Growth | - |
| Next Earnings Announcement | 07/24/2013 |
mrq = Most Recent Quarter; ttm = Trailing Twelve Months
Income Statement for BIIB
Company Profile & Key Executives for BIIB
Biogen Idec Inc. develops, manufactures, and commercializes therapies, focusing on neurology, oncology, and immunology. The Company's products addresses diseases such as multiple sclerosis, non-Hodgkin's lymphoma, rheumatoid arthritis, Crohn's disease, and psoriasis.
| William D Young "Bill"Chairman | George A ScangosChief Executive Officer |
| Susan H AlexanderExec VP/Chief Legal Ofcr/Secy | Paul J ClancyExec VP:Finance/CFO |
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.
Sponsored Financial Commentaries
Advertisement
Top Forex Trading Resources
-
BIIB News
-
Industry News
Advertisement
Advertisement
Sponsored Links
Advertisements
Rate this Page